MECOM and leukemia: Motivated by clinical findings, including MECOM insertions driving leukemias in gene therapy trials,56 we used targeted MECOM degradation with functional genomic readouts to reveal that MECOM primarily acts as a transcriptional repressor, suppressing differentiation programs (a previously underappreciated function).13, 14, 15, 16, 17